Earnings Scheduled For March 21, 2022

Companies Reporting Before The Bell

• Marinus Pharmaceuticals MRNS is likely to report quarterly loss at $0.76 per share on revenue of $3.37 million.

• Pinduoduo PDD is projected to report quarterly earnings at $0.35 per share on revenue of $4.76 billion.

• UroGen Pharma URGN is projected to report quarterly loss at $1.17 per share on revenue of $16.49 million.

• Nortech Systems NSYS is projected to report earnings for its fourth quarter.

Companies Reporting After The Bell

• Augmedix AUGX is expected to report quarterly loss at $0.15 per share on revenue of $6.40 million.

• NexGel NXGL is likely to report earnings for its fourth quarter.

• Dave DAVE is estimated to report earnings for its fourth quarter.

• Alexco Resource AXU is expected to report earnings for its fourth quarter.

• Nike NKE is projected to report quarterly earnings at $0.71 per share on revenue of $10.62 billion.

• FAT Brands FAT is expected to report quarterly loss at $0.29 per share on revenue of $57.50 million.

• TELA Bio TELA is likely to report quarterly loss at $0.55 per share on revenue of $7.98 million.

• Tencent Music Enter Gr TME is estimated to report quarterly earnings at $0.07 per share on revenue of $1.23 billion.

• DarioHealth DRIO is projected to report quarterly loss at $1.06 per share on revenue of $6.05 million.

• HireRight Holdings HRT is projected to report quarterly earnings at $0.07 per share on revenue of $183.35 million.

• Bowman Consulting Group BWMN is estimated to report quarterly loss at $0.07 per share on revenue of $39.62 million.

• Strata Skin Sciences SSKN is estimated to report quarterly loss at $0.02 per share on revenue of $8.97 million.

• Mawson Infrastructure MIGI is estimated to report quarterly earnings at $0.18 per share on revenue of $25.60 million.

• Crexendo CXDO is estimated to report quarterly earnings at $0.03 per share on revenue of $8.82 million.

• Volta VLTA is projected to report quarterly loss at $0.18 per share on revenue of $12.28 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.